Clinical Trials Logo

Clinical Trial Summary

This study evaluates the addition of the CADScorSystem to a standard Diamond-Forrester score guided rule-out strategy in ambulatory patients referred with symptoms suggestive of stable coronary artery disease. Half of the patients will undergo stratification using a Diamond-Forrester score only, while the other half will undergo stratification using a Diamond-Forrester score and a CAD-score. The study hypothesis is that the addition of a CAD-score will reduce unnecessary testing without compromising patient safety.


Clinical Trial Description

Purpose and Rationale for the Study: The declining incidence of obstructive CAD and a good prognosis for patients with stable angina challenges the resource demanding approach recommended in current guidelines. The CADScor®System may be an efficient, fast and low-cost diagnostic tool with a high rule-out efficiency. The current study aims to investigate if the CADScor®System can be added as a rule-out test in patients referred with suspected stable CAD to reduce unnecessary testing Study Hypothesis: A Diamond-Forrester score plus CAD-score guided rule-out strategy is superior to a Diamond-Forrester score guided strategy alone in reducing diagnostic procedures and non-inferior in terms of safety outcomes in patients with symptoms suggestive of stable coronary artery disease. Study Setting: This study will enrol patients without known CAD who are referred with symptoms suggestive for stable CAD for outpatient evaluation at the participating sites. All patients will be symptomatic and require evaluation for suspected CAD. Thus, whether or not the patient chooses to participate in the study, the patient will undergo evaluation for suspected CAD. All the standard NIT modalities and ICA in the study are clinically well established and performed routinely and safely. Experimental testing involves the CADScor®System, for ruling out CAD before any NIT in the intervention group. End of Study: The study will end when all the following have occurred: (1) at least 2000 patients have been randomized, and (2) 12±1 months (1 year) have elapsed since the last patient was randomized. Extended Follow-up after Study Termination: Follow-up might be performed for up to 10 years after randomization. Follow-up information will be extracted from national registers, including information on cardiovascular events and treatments, hospitalizations and ambulatory visits due to cardiovascular events, and causes of death. Statistical methods: A detailed description of the planned statistical analyses will be documented in a separate statistical report and analysis plan (SAP), which will be completed before data base lock. Sample size considerations: A reduction of 15% or more in the primary endpoint is regarded as clinically significant. Assuming an alpha significance level of 0.05, a statistical power of 80% and an expected number of NIT/ICA of 0.94 per patient in the standard care group, a sample size of 314 patients in each arm is needed to ascertain superiority of the intervention. A sample size of 1914 provides 90% power for testing non-inferiority in terms of MACE between the two testing strategies, at an alpha significance level of 0.05. We choose to include 2000 patients, i.e. 1000 patients in each group, allowing for a 4% loss to follow-up and drop out and providing power for the primary endpoint and the secondary MACE non-inferiority endpoint. Statistical analysis: The full analysis set (FAS) will include all randomized patients in whom written informed consent was obtained and in accordance with the intention-to-treat principle all patients will be analysed according to the allocated treatment group. The per-protocol set (PPS) will include only those patients from the FAS who did not have one of the following major protocol violations: inclusion criteria not met, exclusion criteria met, no DF-score calculation, or no CAD-score measurement (intervention group only). Patients who did not receive the randomly allocated CAD-score measurement will be included and analysed in the control group (per protocol analysis). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04121949
Study type Interventional
Source Bispebjerg Hospital
Contact
Status Completed
Phase N/A
Start date July 1, 2019
Completion date September 15, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Recruiting NCT02870764 - The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris Phase 4
Completed NCT04648306 - Restore EF Observational Study
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Not yet recruiting NCT02280850 - Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina Phase 4
Completed NCT04785846 - Registry of RESOLUTE-ONYX™ Zotarolimus-eluting Stent Utilization in Percutaneous Small Vessel Coronary Interventionism.
Completed NCT03759067 - Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina Patients N/A
Not yet recruiting NCT03306550 - Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin N/A
Completed NCT03193294 - CORonary MICrovascular Angina (CorMicA) N/A
Completed NCT04131816 - HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program N/A
Recruiting NCT06075602 - COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease
Recruiting NCT03783351 - Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE) N/A
Recruiting NCT06464042 - Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease
Not yet recruiting NCT05857904 - Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain N/A
Recruiting NCT01838148 - Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia
Terminated NCT02914834 - Acupuncture for Individuals With Stable Angina N/A
Recruiting NCT05825339 - Absolute Flow for Ischemia With No Obstructive Coronary Arteries
Completed NCT05804500 - RecoveryPlus Telerehab Platform Pilot Study N/A
Completed NCT03518645 - Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds N/A
Terminated NCT01550614 - Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease Phase 3